title: Reduction of parasitism tissue by treatment of mice chronically infected with Trypanosoma cruzi with lignano lactones.
abstract: The reduction of parasitism tissue upon treatment with two lignano lactones, namely (-)- cubebin (CUB) and (-)-hinokinin (HNK), was evaluated in the chronic phase of Chagas' disease by quantifying the enzyme beta-galactosidase expressed by the CL B5 clone strain of Trypanosoma cruzi. Tissue karyometry was also performed. Treatment with the assessed lignans led to a larger reduction in parasitism tissue in all evaluated organs, compared with benznidazole (BZN). Oral treatment with CUB or HNK was more effective. Karyometry results demonstrated that the infected control animals had increased nuclear area compared with uninfected controls, indicating cellular hypertrophy. Results also revealed that use of CUB or HNK was able to significantly prevent this increase, and a slight decrease in the nuclear area was observed, compared with mice treated with BZN. Taken together, these data demonstrate that CUB and HNK could be considered as potential compounds for the development of new drugs for treatment of Chagas' disease.
authors.affiliation: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Avenida do Café s/n, Ribeirão Preto, SP, Brazil. vivianee@fcfrp.usp.br
authors.forename: Viviane Rodrigues
authors.initials: VR
authors.lastname: Esperandim
authors.forename: Daniele
authors.initials: D
authors.lastname: da Silva Ferreira
authors.forename: Juliana
authors.initials: J
authors.lastname: Saraiva
authors.forename: Márcio Luis Andrade
authors.initials: ML
authors.lastname: Silva
authors.forename: Eveline Soares
authors.initials: ES
authors.lastname: Costa
authors.forename: Ana Carolina
authors.initials: AC
authors.lastname: Pereira
authors.forename: Jairo Kenupp
authors.initials: JK
authors.lastname: Bastos
authors.forename: Sérgio
authors.initials: S
authors.lastname: de Albuquerque
mesh_terms: D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D052117:Benzodioxoles; D014355:Chagas Disease / Q000188:drug therapy* / Q000469:parasitology; D002908:Chronic Disease; D004149:Dioxoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects / Q000469:parasitology; D007620:Karyometry; D007783:Lactones / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D017705:Lignans / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D013154:Spleen / Q000187:drug effects / Q000469:parasitology; D016896:Treatment Outcome; D014344:Trypanocidal Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D014349:Trypanosoma cruzi / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D001616:beta-Galactosidase / Q000378:metabolism
chemical_list: D052117:Benzodioxoles; D004149:Dioxoles; D007783:Lactones; D017705:Lignans; D014344:Trypanocidal Agents; C475934:hinokinin; D001616:beta-Galactosidase; C433065:cubebin; D015107:4-Butyrolactone